STRUCTURE FORMATION PROCESS OF HYDRATED PORTLAND CEMENT COMPOSITIONS: NANOSCALE LEVEL CONTROL

Durability of cement-like construction materials, as well as durability of cement stone, depends on their humidity resistance, frost resistance, corrosion resistance. All of these properties depend not only on the composition of the original clinker, but also on structural organization at micro-and nanoscale level of hydrated portland cement compositions. In this research the authors used the method of small-angle neutron scattering to define structural parameters of hydrated portland cement compositions on nanoscale level, distribution of calcium hydrate silicate nanoparticles in size, medium nanoparticles radius, fractal dimension. It is shown, that introduction of modifying nanoadditives into portland cement compositions affects structural parameters of a cement stone. The following nanoadditives were used: of artificial (alpha aluminium oxide, gamma aluminum oxide) and of anthropogenic (carbonate and alumo-alkaline sludges) origin, as well as integrated nanoadditives containing surfactants. The change in structural parameters of portland cement compositions with nanoadditives in the process of hydration is investigated. It is shown that use of nanoadditives allows to control the process of forming the structure of hydrated portland cement composition on the nanoscale level, directly affect the values of structural parameters and, as a result, modify properties of cement stone

Evaluate of motivation to education of distance education students who study on pharmaceutical faculty of UGMU

In the article research results of motivation to the higher pharmaceutical education reception of distance education students with a method of survey are considered.В статье рассмотрены результаты исследования мотивации к получению высшего фармацевтического образования студентов, обучающихся на заочной форме обучения, методом анкетирования

Fine-tuning of Silica Coating Procedure for Preparation of Biocompatible and Bright Pbs/Sio2 Qds

Near-infrared semiconductor PbS quantum dots (QDs) with emission in biological transparency window are promising material for in vivo biolabelling and deep-tissue imaging of biological specimen. Among various approaches that render initially hydrophobic and toxic QDs biocompatible, the growth of a silica shell on the QD surface represents an efficient method to minimize QD toxicity. Nevertheless, it is important to preserve QDs emission properties after the silica coating procedure. Here we report on the optimal parameters of this procedure which allow to obtain a stable silica shell and maintain the optical properties of initial PbS QDs. Furthermore, we show that PbS QDs with the optimal SiO2 shell retain their luminescence quantum yield even after condensation into a solid film. Thus, our procedure can become a basis in development of bright, receptor-targeted NIR fluorescent probes for in vivo tumor imaging. Keywords: quantum dot, SiO2 shell, bioimagin

Evaluation of students hostel conditions by students of pharmacy

The article presents and discusses the Pharmaceutical students survey’s results of all courses from the first to the fifth who live in the hostels of the Ural State Medical University.В статье приводятся и обсуждаются результаты анкетирования студентов фармацевтического факультета, обучающихся на 1-5 курсах и проживающих в корпусах общежитий Уральского государственного медицинского университета

Study of motivation to labor activity of students 4-5 courses of pharmaceutical faculty

The article presents the results of studying student’s motivation who learn on the 4-5 year in the pharmaceutical faculty of the Ural state medical university. The problems of motivation of students to work activity, their professional intentions are considered.В статье приведены результаты изучения трудовой мотивации студентов 4-5 курса фармацевтического факультета УГМУ. Рассмотрены проблемы мотивации обучающихся к трудовой деятельности, их профессиональные намерения

The development of radio and 3G based telemetry system for the remote gas accounting and control nodes

In this article we have described the use of vortex and recently developed ultrasonic flowmeters with high dynamic range of 1 to 1500 for industrial applications. Its software and the software of corresponding computing device is able to avoid gas leakage, to minimize energy consumption and to save human resources while maintaining metrological data. Described is the low power consumption that makes it possible to use this ultrasonic flowmeter in hard remote environment without direct management for a period of several month

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the final analysis of efficacy and safety from COLUMBA after a median of 29.3 months follow-up (additional 21.8 months after the primary analysis). In total, 522 patients were randomized (DARA SC, n=263; DARA IV, n=259). With longer follow-up, DARA SC and DARA IV continued to show consistent efficacy and maximum trough daratumumab concentration as compared with the primary analysis. The overall response rate was 43.7% for DARA SC and 39.8% for DARA IV. The maximum mean (standard deviation [SD]) trough concentration (cycle 3, day 1 pre-dose) of serum DARA was 581 (SD, 315) µg/mL for DARA SC and 496 (SD, 231) µg/mL for DARA IV. Median progression-free survival was 5.6 months for DARA SC and 6.1 months for DARA IV; median overall survival was 28.2 months and 25.6 months, respectively. Grade 3/4 treatment-emergent adverse events occurred in 50.8% of patients in the DARA SC group and 52.7% in the DARA IV group; the most common (≥10%) were thrombocytopenia (DARA SC, 14.2%; DARA IV, 13.6%), anemia (13.8%; 15.1%), and neutropenia (13.1%; 7.8%). The safety profile remained consistent with the primary analysis after longer follow-up. In summary, DARA SC and DARA IV continue to demonstrate similar efficacy and safety, with a low rate of infusion-related reactions (12.7% vs. 34.5%, respectively) and shorter administration time (3-5 minutes vs. 3-7 hours) supporting DARA SC as a preferable therapeutic choice

Adaptation students who study on the first course of pharmaceutical faculty to student life

This article presents the results of a questionnaire survey of students who study on the first course of the pharmaceutical faculty of USMA. The purpose of the study was to find out whether students are satisfied with the quality and methods of teaching, identify the existing problems of adaptation of first-year students.В данной статье приведены результаты анкетирования обучающихся на 1 курсе фармацевтического факультета УГМУ. Целью исследования было выяснить, довольны ли студенты качеством и методами обучения, выявить существующие проблемы адаптации студентов-первокурсников

Once-weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial

Background Selinexor with dexamethasone has demonstrated activity in patients with heavily pretreated multiple myeloma (MM). In a phase 1b/2 study, the combination of oral selinexor with the proteasome inhibitor (PI) bortezomib, and dexamethasone (SVd) induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. The aim of this trial was to evaluate the clinical benefit of weekly SVd versus standard bortezomib and dexamethasone (Vd) in patients with previously treated MM. Methods This phase 3, randomised, open label trial was conducted at 123 sites in 21 countries. Patients who were previously treated with one to three lines of therapy, including PIs were randomised (1:1) to selinexor (100 mg once-weekly) plus bortezomib (1·3 mg/m2 once-weekly) and dexamethasone (20 mg twice-weekly) [SVd] or bortezomib (1·3 mg/m2 twice-weekly) and dexamethasone (20 mg 4 times per week) [Vd]. Randomisation was done using interactive response technology and stratified by previous PI therapy, lines of treatment, and MM stage. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Patients who received at least one dose of study treatment were included in the safety population. This trial is registered at ClinicalTrials.gov, NCT03110562. Findings Between June 2017 and February 2019, 402 patients were randomised: 195 to SVd and 207 to Vd. Median PFS was 13·93 (95% CI 11·73–NE) with SVd versus 9·46 months (8·11–10·78) with Vd; HR 0·70, [95% CI 0·53–0·93]; P=0.0075. Most frequent grade ≥3 adverse events (SVd vs Vd) were thrombocytopenia (77 [40%] vs 35 [17%]), fatigue (26 [13%] vs 2 [1%]), anaemia (31 [16%] vs 20 [10%]), and pneumonia (22 [11%] vs 22 [11%]). Peripheral neuropathy rates (overall, 32·3% vs 47·1%; OR 0·52, [95% CI 0·35-0·79]; P=0.0010 and grade ≥2, 21·0% vs 34·3%; OR 0·50, [95% CI 0·32-0·79]; P=0.0013) were lower with SVd. There were 47 (24%) deaths on SVd and 62 (30%) on Vd. Interpretation Once-weekly SVd is a novel, effective, and convenient treatment option for patients with MM who have received 1-3 prior therapies. Funding Karyopharm Therapeutics In